Abstract
Multiple Myeloma (MM) is a common hematologic malignancy of plasma cells representing an excellent model of epigenomics dysregulation in human disease. Importantly, these findings, in addition to providing a better understanding of the underlying molecular changes leading to this malignance, furnish the basis for an innovative therapeutic approach. Histone deacetylase inhibitors (HDACIs), including Vorinostat and Panobinostat, represent a novel class of drugs targeting enzymes involved in epigenetic regulation of gene expression, which have been evaluated also for the treatment of multiple myeloma. Although the clinical role in this setting is evolving and their precise utility remains to be determined, to date that single-agent anti-MM activity is modest. More importantly, HDACIs appear to be synergistic both in vitro and in vivo when combined with other anti-MM agents, mainly proteasome inhibitors including bortezomib. The molecular basis underlying this synergism seems to be multifactorial and involves interference with protein degradation as well as the interaction of myeloma cells with microenvironment. Here we review molecular events underling antitumor effects of HDACIs and the most recent results of clinical trials in relapsed and refractory MM.
Keywords: Multiple myeloma, HDACIs, apoptosis, proteasome inhibitor, novel therapy
Current Pharmaceutical Design
Title:New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Volume: 19 Issue: 4
Author(s): Michele Cea, Antonia Cagnetta, Marco Gobbi, Franco Patrone, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Affiliation:
Keywords: Multiple myeloma, HDACIs, apoptosis, proteasome inhibitor, novel therapy
Abstract: Multiple Myeloma (MM) is a common hematologic malignancy of plasma cells representing an excellent model of epigenomics dysregulation in human disease. Importantly, these findings, in addition to providing a better understanding of the underlying molecular changes leading to this malignance, furnish the basis for an innovative therapeutic approach. Histone deacetylase inhibitors (HDACIs), including Vorinostat and Panobinostat, represent a novel class of drugs targeting enzymes involved in epigenetic regulation of gene expression, which have been evaluated also for the treatment of multiple myeloma. Although the clinical role in this setting is evolving and their precise utility remains to be determined, to date that single-agent anti-MM activity is modest. More importantly, HDACIs appear to be synergistic both in vitro and in vivo when combined with other anti-MM agents, mainly proteasome inhibitors including bortezomib. The molecular basis underlying this synergism seems to be multifactorial and involves interference with protein degradation as well as the interaction of myeloma cells with microenvironment. Here we review molecular events underling antitumor effects of HDACIs and the most recent results of clinical trials in relapsed and refractory MM.
Export Options
About this article
Cite this article as:
Michele Cea, Antonia Cagnetta, Marco Gobbi, Franco Patrone, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson , New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040734
DOI https://dx.doi.org/10.2174/1381612811306040734 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment
Mini-Reviews in Medicinal Chemistry DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Myc Decoy Oligodeoxynucleotide Inhibits Growth and Modulates Differentiation of Mouse Embryonic Stem Cells as a Model of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Status Epilepticus: An Overview
Current Drug Metabolism Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets